Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1322-1334

  Flipo, Marion ^a,b,c   Beghyn, Terence ^a,b,c   Leroux, Virginie ^a,b,c   Florent, Isabelle ^d   Deprez, Benoit P ^a,b,c   Deprez Poulain, Rebecca F ^a,b,c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ANTIMALARIAL AGENT; ENZYME INHIBITOR; HYDROXAMIC ACID; MALONIC ACID;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; RAT; STRUCTURE ACTIVITY RELATION;

EID: 33947632299     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061169b     Document Type: Article

References (48)

1. 1.3 million deaths in 2004 (World Health Organization Global report 2004, Geneva, 2004), 3 billion people at risk in 2005 (Word Malaria Report 2005 from Roll Back Malaria Partnership, available at www.rbm.who.int/wmr2005/).
2. Malenga, G.; Palmer, A.; Staedke, S.; Kazadi, W.; Mutabingwa, T.; Ansah, E.; Barnes, K. I.; Whitty, C. J. Antimalarial treatment with artemisinin combination therapy in Africa. Br. Med. J. 2005, 331, 706-707.
3. Edwards, G.; Biagini, G. A. Resisting resistance: Dealing with the irrepressible problem of malaria. Br. J. Clin. Pharmacol. 2006, 61, 690-693.
4. Bloland, P. B. Drug resistance in malaria, World Health Organization report; World Health Organization: Geneva, Switzerland, 2001.
5. Phillips, M.; Phillips-Howard, P. A. Economic implications of resistance to antimalarial drugs. Pharmacoeconomics 1996,10, 225-238.
6. Greenwood, B. M.; Bojang, K.; Whitty, C. M.; Targett, G. A. Malaria. Lancet 2005, 565, 1487-1498.
7. Plasmodium genomics special issue. Nature 2002, special issue, October 3, 2002.
8. Yeh, I.; Altman, R. B. Drug Targets for Plasmodium falciparum: A post-genomic review/survey. Mini-Rev. Med. Chem. 2006, 6, 177-202.
9. Woster, P. M. New Therapies for Malaria. In Annu. Rep. Med. Chem.; Doherty, A. M., Ed.; Academic Press: New York, 2003; Vol. 38, pp 203-211.
10. For a review on chemotherapy research: Wiesner, J.; Ortmann, R.; Jomaa, H.; Schitser, M. New antimalarial drugs. Angew. Chem., Int. Ed. 2003, 42, 5274-5293.
11. O'Donnell, R. A.; Blackman, M. J. The role of malaria merozoite proteases in red blood cell invasion. Curr. Opin. Microbiol. 2005, 8, 422-427.
12. Blackman, M. J. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Curr. Drug Targets 2000, 1, 59-83.
13. Blackman, M. J. Proteases in host cell invasion by the malaria parasite. Cell Microbiol. 2004, 6, 893-903.
14. Rosenthal, P. J. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol. 2002, 9, 140-145.
15. Wu, Y.; Wang, X.; Liu, X.; Wang, Y. Data-Mining Approaches Reveal Hidden Families of Proteases in the Genome of Malaria Parasite. Genome Res. 2003, 13, 601-616.
16. Klemba, M.; Gluzman, I.; Goldberg, D. E. A Plasmodium falciparum Dipeptidyl Aminopeptidase I Participates in Vacuolar Hemoglobin Degradation. J. Biol. Chem. 2004, 279, 43000-43007.
17. Withers-Martinez, C.; Jean, L.; Blackman, M. J. Subtilisin-like proteases of the malaria parasite. Mol. Microbiol. 2004, 53, 55-63.
18. Ersmark, K.; Feierberg, I.; Bjelic, S.; Hamelink, E.; Hackett, F.; Blackman, M. J.; Hulten, J.; Samuelsson, B.; Aqvist, J.; Hallberg, A. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J. Med. Chem. 2004, 47, 110-122.
19. Ersmark, K.; Nervall, M.; Hamelink, E.; Janka, L. K.; Clemente, J. C.; Dunn, B. M.; Blackman, M. J.; Samuelsson, B.; Aqvist, J.; Hallberg, A. Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J. Med. Chem. 2005, 48, 6090-6106.
20. Ersmark, K.; Nervall, M.; Gutierrez-de-Teran, H.; Hamelink, E.; Janka, L. K.; Clemente, J. C.; Dunn, B. M.; Gogoll, A.; Samuelsson, B.; Qvist, J.; Hallberg, A. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg. Med. Chem. 2006, 74, 2197-2208.
21. Nezami, A.; Kimura, T.; Hidaka, K.; Kiso, A.; Liu, J.; Kiso, Y.; Goldberg, D. E.; Freire, E. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 2003, 42, 8459-8464.
22. Andrews, K. T.; Fairlie, D. P.; Madala, P. K.; Ray, J.; Wyatt, D. M.; Hilton, P. M.; Melville, L. A.; Beattie, L.; Gardiner, D. L.; Reid, R. C.; Stoermer, M. J.; Skinner-Adams, T.; Berry, C.; McCarthy, J. S. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 2006, 50. 639-648.
23. Desai, P. V.; Patny, A.; Sabnis, Y.; Tekwani. B.; Gut. J.; Rosenthal, P.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. 2004, 47, 6609-6615.
24. Desai, P. V.; Patny, A.; Gut, J.; Rosenthal, P. J.; Tekwani, B.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J. Med. Chem. 2006, 49, 1576-1584.
25. Lee, B. J.; Singh, A.; Chiang, P.; Kemp, S. J.; Goldman, E. A.; Weinhouse, M. I.; Vlasuk, G. P.; Rosenthal, P. J. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother. 2003, 47, 3810-3814.
26. Batra, S.; Sabnis, Y. A.; Rosenthal, P. J.; Avery, M. A. Structure-based approach to falcipain-2 inhibitors: Synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. Bioorg. Med. Chem. 2003, 11, 2293-2299.
27. Greenbaum, D. C.; Mackey, Z.; Hansell, E.; Doyle, P.; Gut, J.; Caffrey, C. R.; Lehrman, J.; Rosenthal, P. J.; McKerrow, J. H.; Chibale, K. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. 2004, 47, 3212-3219.
28. Verhelst, S. H.; Witte, M. D.; Arastu-Kapur, S.; Fonovic, M.; Bogyo, M. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases. ChemBioChem 2006, 7, 943-950.
29. Murata, C. E.; Goldberg, D. E. Plasmodium falciparum falcilysin. J. Biol. Chem. 2003, 278, 38022-38028.
30. Gardiner, D. L.; Trenholme, K. R.; Skinner-Adams, T. S.; Stack, C. M.; Dalton, J. P. Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. J. Biol. Chem. 2006, 281, 1741-1745.
31. Florent, I.; Derhy, Z.; Allary, M.; Monsigny, M.; Mayer, R.; Schrevel, J. A Plasmodium falciparum aminopeptidase gene belonging to the M1 family of zinc-metallopeptidases is expressed in erythrocytic stages. Mol. Biochem. Parasitol. 1998, 97, 149-160.
32. Chen, X.; Chong, C. R.; Shi, L.; Yoshimoto, T.; Sullivan, D. J.; Liu, J. O. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14548-14553.
33. Ponpuak, M.; Klemba, M.; Park, M.; Gluzman, I. Y.; Lamppa, G. K.; Golberg, D. E. A role for falcilysin in transit peptide degradation in the Plasmodium falciparum apicoplast Mol. Microbiol. 2006, 63, 314-334.
34. PfA-M1 is referenced as MAL8P1.56 in PlasmoDB (http://plasmod-b.org).
35. Allary, M.; Schrevel, J.; Florent, I. Properties, stage-dependent expression and localization of Plasmodium falciparum M1 family zinc-aminopeptidase. Parasitology 2002, 125, 1-10.
36. Kitjaroentham, A.; Suthiphongchai, T.; Wilarairat, P. Effect of metalloprotease inhibitors on invasion of red blood cell by Plasmodium falciparum. Acta Trop. 2006, 97, 5-9.
37. Deprez-Poulain, R.; Melnyk, P. 1,4-bis(3-aminopropyl)piperazine libraries: from the discovery of classical chloroquine-like antimalarials to the identification of new targets. Comb. Chem. High Throughput Screening 2005, 8, 39-48.
38. Flipo, M.; Florent, I.; Grellier, P.; Sergheraert, C.; Deprez-Poulain, R. Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2659-2662.
39. Flipo, M.; Beghyn, T.; Charton, J.; Leroux, V. A.; Deprez, B. P.; Deprez-Poulain, R. F. A library of novel hydroxamic acids targeting the metallo-protease family: Design, parallel synthesis and screening. Bioorg. Med. Chem. 2007, 75, 63-76.
40. Zhang, J. H.; Chung, T. D.; Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screening 1999, 4, 67-73.
41. Sicker, D.; Rabe, A.; Zakrzewski, A.; Mann, G. Synthese substituierter N-hydroxylactame, lactame, chinolin-N-oxide und chinoline durch katalysierte reduktive cyclisierung von 2-nitrocinnamoyl-verbindungen mit Wasserstoff/Platinschwarz. J. Prakt. Chem. 1987,329, 1063-1070.
42. ABS was calculated using an in-house PipelinePilot™ (from Scitegic) protocol based on the following publication: Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48, 3164-3170. This article underlines the fact that the polar surface area (PSA) and the rule-of-five govern bioavailability of anionic compounds and of neutral, zwitterionic, or cationic compounds, respectively.
43. Hadjuk, P. J.; Shuker, S. B.; Nettesheim, D. G.; Craig, R.; Augeri, D. J.; Betebenner, D.; Albert, D. H.; Guo, Y.; Meadows, R. P.; Xu, L.; Michaelides, M.; Davidsen, S. K.; Fesik, S. W. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 2002, 45, 5628-5639.
44. Nagaoka, Y.; Maeda, T.; Kawai, Y.; Nakashima, D.; Oikawa, T.; Shimoke, K.; Ikeuchi, T.; Kuwajima, H.; Uesato, S. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: Hydrophilic hydroxamates and 2-aminobenzamide-containig derivatives. Eur. J. Med. Chem. 2006, 41, 697-708.
45. These references explain the impact of the high concentration of carbonic anhydrase on the pharmacokinetics of a zinc binding drug, (a) Shank, R. P.; Doose, D. R.; Streeter, A. J.; Bialer, M. Plasma and whole blood pharmacokinetics of topiramate: The role of carbonic anhydrase. Epilepsy Res. 2005, 63 (2-3), 103-112.
46. (b) Martens-Lobenhoffer, J.; Banditt, P. Clinical pharmacokinetics of dorzolamide. Clin. Pharmacokinet. 2002, 41 (3), 197-205.
47. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture. Science 1976, 193, 673-675.
48. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.